Pertuzumab

What it is used for

PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.

( 1.2, 2.2, 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2, 2.2, 14.3 ) 1.1 Metastatic Breast Cancer (MBC) PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Early Breast Cancer (EBC) PERJETA is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.

the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.

Side effects, and when to stop

The following adverse reactions are discussed in greater detail in other sections of the label:

• Left Ventricular Dysfunction
• Embryo-Fetal Toxicity
• Infusion-Related Reactions
• Hypersensitivity Reactions/Anaphylaxis

Who should not take it

PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.

Storing it

Storage and Handling

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until time of use to protect from light.

Do not freeze. Do not shake.

DO NOT FREEZE. DO NOT SHAKE.